Health Condition 1: null- Patients Suffering From Chronic Asthama
Conditions
Interventions
Intervention1: Montelukast 10mg + Acebrophylline 100mg: Orally once daily in the evening for 28 Days
Control Intervention1: Montelukast 10mg: Orally once daily in the evening for 28 Days
Sponsors
Biocon Ltd
Bioequivalence Study Centre
TAAB Biostudy Services
Eligibility
Inclusion criteria
Inclusion criteria: i) Male and female patients in the age group of 18- 64 years. ii) Patients clinically diagnosed as suffering from mild asthma as indicated by an FEV1 between 60 and 85% of predicted. iii) Requiring inhaled ß2-agonists on an as-needed basis iv) Stable asthma; there should have been no exacerbations or need for any other treatment for one month, and no hospitalizations for asthma should have occurred with-in 3 months of the pre study visit. v) Nonsmokers for at least 1 yr (with a smoking history of no more than 10 pack-yrs) vi) ACT score 19 [18,19] vii) ACQ score 1.5 [20] viii) Subjects or legal representatives willing to give informed consent. ix) Patient must not have received any drug similar to active or comparator group within 2 weeks of commencement of the study. x) Females of childbearing potential should have a negative pregnancy test at the pre study visit and should agree to use contraception during the study.
Exclusion criteria
Exclusion criteria: i) History of hypersensitivity reaction or any specific groups. ii) Presence of severe hepatic or renal disorders, iii) Pregnancy or lactation iv) Alcoholics and heavy smokers. v) Patients on following medications: Anticonvulsant drugs, Rifampicin, Erythromycin /other macrolides, Ciprofloxacin (not ofloxacin) Cimetidine (not ranitidine). vi) Patients on anti TB drugs and or diagnosed to be suffering from tuberculosis. vii) Patients suffering from HIV infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvements are the primary end-points and are defined as patients who has: 1.Improvement in pulmonary function test (FEV1 & FEV1/ FVC) 2.Improvement in Asthma Control Tests Score (Appendix IV) 3.Improvement in Asthma Control Questionnaires Score (Appendix V) 4.(Reduction in) Number of as-needed ß2-agonist puffs used 5.Percentage of unscheduled or emergency asthma-related (primary care) consultations during the study periodTimepoint: 28 days | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Vanita Sabhait
Outcome results
None listed